CD81 通过阻断 CD274/PD-L1 的选择性自噬降解驱动放射抵抗性胶质母细胞瘤的免疫逃逸
CD81 drives immune evasion in radioresistant glioblastoma by blocking selective autophagic degradation of CD274/PD-L1.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
从冷中走出：克服髓母细胞瘤的敌对免疫微环境
英文原题：Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma.
查看英文原题
Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
髓母细胞瘤是一种侵袭性脑肿瘤，主要发生于儿童。尽管采用强化治疗，许多患者仍死于该病，迫切需要新疗法。免疫疗法已在多种癌症中显示出前景，但髓母细胞瘤突变负荷低、免疫效应细胞浸润有限且微环境具有免疫抑制性，因此人们曾认为该肿瘤不太可能对免疫疗法产生应答。然而，新兴证据正挑战这一观点。本文回顾近期临床前和临床研究，这些研究发现了髓母细胞瘤免疫逃逸机制，并重点介绍可能为髓母细胞瘤患者及其家人带来新希望的潜在治疗干预。
展开英文摘要原文
Medulloblastoma is an aggressive brain tumor that occurs predominantly in children. Despite intensive therapy, many patients die of the disease, and novel therapies are desperately needed. Although immunotherapy has shown promise in many cancers, the low mutational burden, limited infiltration of immune effector cells, and immune-suppressive microenvironment of medulloblastoma have led to the assumption that it is unlikely to respond to immunotherapy.
However, emerging evidence is challenging this view. Here we review recent preclinical and clinical studies that have identified mechanisms of immune evasion in medulloblastoma, and highlight possible therapeutic interventions that may give new hope to medulloblastoma patients and their families.
论文信息
- 作者
- Eisemann T、Wechsler-Reya RJ
- 单位
- Tumor Initiation and Maintenance Program, National Cancer Institute-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California 92037, USA.United States
- 文献类型
- 综述 · 非美国政府资助研究 · 美国 NIH 资助研究
- 期刊
- Genes & development2022 May 1
- 原文标识
- PubMed 35680424 · DOI 10.1101/gad.349538.122
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →